Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical, Inc. (NASDAQ:TNON) announced its participation in Benzinga's All Access investor event on September 16, 2022. CEO Steve Foster will present and host a Q&A session at 10:00 a.m. Eastern time, aiming to discuss the company’s FDA-cleared surgical implant system for sacroiliac joint fixation/fusion surgery. This event provides a platform to highlight Tenon's upcoming national launch, targeting a significant opportunity in a currently underserved market.
Tenon Medical (NASDAQ:TNON) announced its participation in upcoming virtual conferences, including the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, and the A.G.P.'s Virtual MedTech Conference on September 21, 2022. CEO Steve Foster and CFO Steven Van Dick will be available for one-on-one meetings. Tenon Medical specializes in a proprietary, FDA-cleared surgical implant system aimed at optimizing SI Joint fixation/fusion surgery, with plans for a national launch to address market needs.
Tenon Medical (NASDAQ:TNON) reported a 514% year-over-year revenue increase in Q2 2022, reaching $135,000, driven by a 433% rise in surgical procedures utilizing its Catamaran™ SI Joint Fusion System. Despite increased revenue, the company faced a gross loss of $136,000 due to higher operational overhead, shifting from a gross profit of $13,000 a year prior. Operating losses expanded to $5.5 million. The company ended Q2 with $16 million in cash and investments, supporting ongoing growth and commercialization efforts, including 21 physician workshops held to promote their innovative solutions.
Tenon Medical, a medical device company, closed a $16 million IPO on April 29, 2022, and began trading on Nasdaq under the ticker TNON. For Q1 2022, the company reported revenue of $71,000, a 373% increase from Q1 2021, driven by an 80% rise in surgical procedures using the CATAMARAN SIJ Fusion System. However, gross loss increased to $(204,000), and operating losses reached $2.1 million, up from $189,000 in the previous year. The company holds $4.7 million in cash to fund growth initiatives.
Tenon Medical has successfully closed its initial public offering, selling 3.2 million shares of common stock at $5.00 per share, totaling $16.0 million in gross proceeds. The IPO was facilitated by The Benchmark Company, LLC and Valuable Capital Limited as underwriters. The stock now trades on the Nasdaq Capital Market under the ticker TNON. Proceeds from the offering are expected to support Tenon's national launch of its proprietary surgical implant system for sacroiliac joint fixation, targeting a significant market opportunity.